Wang's [26] study in NSCLC exhibited that patients with high BRCA1 expression had longer progression free survival (PFS) and overall survival (OS) Quinn's [27] study showed that overall median survival for higher-BRCA1-expressing patients was found to increase following taxane-containing chemotherapy. The gene discussed is BRCA1; the disease is non-small cell lung carcinoma.